Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.72 -1.84%

-$0.18 today

Market cap
$1.27B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.34M

Average 4.58M

Income Statement

Follow revenue through to earnings.

Revenue

$1.12B

FY 2025 · Annual

+64.7% YoY

Operating Income

$563.27M

FY 2025 · Annual

Net Income

$440.30M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

NVAX Earnings Waterfall · TTM

NASDAQ:NVAX · Revenue to Net Income

Key Ratios

EPS$-0.60
Gross Margin81.1%
Net Margin-59.4%
P/E Ratio-4.7
P/S Ratio10.3

Analysis

$596.3M of revenue converted into -$87.8M of net income for the selected period. Gross margin is 81.1% and net margin is -59.4%, showing how much revenue survives after costs and taxes. EPS is $-0.60, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportOct 29, 2026
SC 13D/ASC 13D/A filingOct 16, 2026

How much revenue does NVAX generate?

Novavax, Inc. (NVAX) reported $1.12B of revenue in fiscal 2025.

Is NVAX profitable?

Novavax, Inc. (NVAX) reported $440.30M of net income, with a net margin of 39.2%.